Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

被引：0
|
作者：
Muhammad Wasif Saif
K. I. Syrigos
S. Hotchkiss
J. Shanley
J. Grasso
T. M. Ferencz
K. Syrigos
M. M. Shah
机构：
[1] Yale University School of Medicine,Section of Medical Oncology
[2] Athens School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 65卷
关键词：
Cetuximab (Erbitux); Panitumumab; Epidermal growth factor receptor (EGFR); Colorectal cancer; Hypersensitivity reaction; Infusion reaction; Desensitization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 112
页数：5
相关论文
共 50 条
  • [31] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
    Di Nicolantonio, Federica
    Martini, Miriam
    Molinari, Francesca
    Sartore-Bianchi, Andrea
    Arena, Sabrina
    Saletti, Piercarlo
    De Dosso, Sara
    Mazzucchelli, Luca
    Frattini, Milo
    Siena, Salvatore
    Bardelli, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5705 - 5712
  • [32] Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer
    Hata A.
    Katakami N.
    Fujita S.
    Takatori K.
    Horai A.
    Kitajima N.
    Terashima K.
    Journal of Gastrointestinal Cancer, 2013, 44 (4) : 456 - 459
  • [33] Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience
    Marino, Antonella
    Caliolo, Chiara
    Sponziello, Francesco
    Nacci, Angelo
    Quaranta, Annamaria
    Mazzoni, Enrica
    Federico, Federica
    Rizzo, Pietro
    Calvani, Nicola
    Orlando, Laura
    Schiavone, Paola
    Fedele, Palma
    Amico, Maria D'
    Chetri, Maria Concetta
    Cinefra, Margherita
    Ferrara, Pasqualinda
    Cinieri, Saverio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Cetuximab rechallenge in metastatic colorectal cancer patients
    Nogueira, A.
    Rodrigues, J.
    Jacinto, P.
    Ribeiro, J.
    Bonito, N.
    Marques, M.
    Gervasio, H.
    ANNALS OF ONCOLOGY, 2016, 27 : 49 - 50
  • [35] Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy
    Graham, Christopher N.
    Maglinte, Gregory A.
    Schwartzberg, Lee S.
    Price, Timothy J.
    Knox, Hediyyih N.
    Hechmati, Guy
    Hjelmgren, Jonas
    Barber, Beth
    Fakih, Marwan G.
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1376 - 1391
  • [36] Successful oxaliplatin desensitization protocol in a patient with colorectal metastatic cancer
    de Lira-Quezada, Cindy E.
    Villarreal-Gonzalez, Rosalaura V.
    Gonzalez-Diaz, Sandra N.
    Carrasco-Diaz, Ligia L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (02) : 490 - 493
  • [37] Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada
    Pettigrew, M.
    Kavan, P.
    Surprenant, L.
    Lim, H. J.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (02) : 135 - 147
  • [38] Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Larsen, Finn Ole
    Pfeiffer, Per
    Nielsen, Dorte
    Skougaard, Kristin
    Qvortrup, Camilla
    Vistisen, Kirsten
    Fromm, Anne-Lene
    Jorgensen, Trine L.
    Bjerregaard, Jon K.
    Hoegdall, Estrid
    Jensen, Benny V.
    ACTA ONCOLOGICA, 2011, 50 (04) : 574 - 577
  • [39] Seizure activity during cetuximab infusion in a patient with metastatic colorectal cancer
    McClellan, Nicole H.
    Bell, William A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (21) : 1881 - 1884
  • [40] Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
    Bardelli, Alberto
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1254 - 1261
12345